**PROTOCOL FOR PHARMACIST** **PRESCRIBING OF DANGEROUS DRUGS IN CONJUNCTION WITH POINT-OF-CARE TESTING (POCT)**

**TEST-TO-TREAT CERTIFICATION TRAINING OUTLINE**

* POCT Definitions
	+ CLIA Waived Tests
	+ CLIA Pertaining to Test-to-Treat
	+ Requirements for Performing CLIA Waived Tests
	+ Process for Obtaining CLIA Waiver
* Lab Quality Control and Good Laboratory Practices
* New Mexico Board of Pharmacy Protocol
	+ Evolution of the NM Test-to-Treat Protocol
	+ Protocol for Pharmacists Prescribing of Dangerous Drugs in Conjunction with POCT
	+ Pharmacist Mandates
* Pharmacists Role in Test-To-Treat
	+ Need for Service
	+ Evolution of Pharmacy-Based Testing and Treatment
	+ Patient Centered Care
	+ Opportunities for Expanded Care
* Resources/Toolkit
* POCT Testing Technology
	+ Evolution of POCT Technology
	+ Lateral Flow Assays
* Test Definitions
	+ Test Sensitivity
	+ Test Specificity
	+ PPV (Positive Predictive Value)
	+ NPV (Negative Predictive Value)
* Test Interpretation of Results
	+ Factors Influencing Test Performance and Interpretation of Test Results
* Disease/Condition \*go through each approved\*
	+ Epidemiology/Pathophysiology
	+ Signs/Symptoms
	+ Disease Complications
* Screening/Protocol Procedures
	+ Patient Screening and Consent
	+ Patient Work-Up, Symptoms, Medical History, Allergies, etc.
	+ Vitals as applicable
	+ Physical Assessment and Interpretation
	+ Barriers/Limitations
	+ Condition Guidelines
* POCT Collection
	+ Hands On Demonstration
	+ Physical Assessment Demonstration, various techniques as applicable; i.e. throat swab, nasal swab, fluid collection, evaluation/feedback
* Treatment Plan/IDSA Guidelines
	+ Non-pharmacological
	+ Drug resistance
	+ Supporting Antimicrobial Stewardship
* Counseling
	+ Side Effects
	+ Adverse Effects
	+ Complications
* Referral Requirements (Case Scenarios, Various)
* Records/Reporting (State Specific/Protocol Specific)
	+ Notifiable/Reportable Conditions
* Reimbursement Procedures (State Specific)
* Patient Case Assessment Cumulative/Feedback